Unique Research · Unique Friend / Event · December 5, 2022
Interview with Qiao Minghui, founder & CEO of Yuemi Tech (悦米科技) — data-driven pharma/device digital-marketing solutions (private-domain doctor–patient, integrated care, data/biz mid-platforms). Shanghai “专精特新”; dozens of software copyrights; national tech SME + high-tech firm.
Stack: MedChat-based smart mid-platform; MedEvent scene systems; WeChat private-domain ops bridging online/offline; open platform integrating academic libraries, societies, DSP/DMP for closed-loop digital marketing. 7 years: 150+ top domestic/foreign pharma-device clients; 500+ innovative-drug pipelines. Clients: Roche, AbbVie, Abbott, J&J, Medtronic; HengRui, Hansoh, Yangtze River, CTTQ; Fudan-Zhangjiang, Zai Lab, Henlius. 2022 revenue growth expected >80%. Prior investors: Kaiyu Group, Sinopharm CICC; Aug 2021 multi-million A round. New round open — Unique Capital as FA. Team >150 (60%+ from pharma marketing/enterprise services; core 15y+ tenure). CDP suite: MedLink + MedData + MedBI for precise academic promotion.
2022 milestone: MedOS specialty-disease pharma marketing collaboration platform validated and entering commercial promotion — patient-centric, integrating Sinopharm strategic-shareholder resources around clinical pathways: recruit → educate → follow-up → manage; multi-vendor products/services; tens of millions RMB into disease KG, ops systems, data-driven platforms. Cases: doctor–patient–enterprise triad platform; MedLink full-funnel tracking for sales lift. 2023: deepen channel/doctor/patient pillars; expand innovative-drug + C-end; evolve from B2B systems to full-course platform linking pharma, doctors, patients, innovative payment, DTP pharmacies. Policy (VBP, insurance cost control, two-invoice) + AI/big data push digital marketing from support act to lead; MNCs/innovators may leap in 2–3 years, broader peers in ~5. Pharma firms already allocate ~10–30% budgets to digital channels post-COVID.
— END —